Apolllomics shares are trading higher after the company announced preliminary data and a 43% response rate for its phase 2 SPARTA trial of Vebreltinib.
Portfolio Pulse from Benzinga Newsdesk
Apolllomics shares are trading higher following the announcement of preliminary data and a 43% response rate for its phase 2 SPARTA trial of Vebreltinib.
August 13, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apolllomics shares are experiencing an upward trend due to positive preliminary data from its phase 2 SPARTA trial of Vebreltinib, showing a 43% response rate.
The positive preliminary data from the phase 2 SPARTA trial of Vebreltinib, showing a 43% response rate, is a significant milestone for Apolllomics. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100